Key PointsVertex Pharmaceuticals' core business remains healthy, and it has a portfolio of kidney disease candidates that could top $10 billion in annual sales.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.
